Avastin Plus Chemotherapy Improves Progression-Free and Overall Survival in Mucosal Melanoma

Source: Cure Today, January 2021

Avastin (bevacizumab) with carboplatin plus paclitaxel improved overall survival (OS) and progression-free survival (PFS) compared with carboplatin and paclitaxel alone in patients with metastatic mucosal melanoma, according to findings from a phase 2 study published in the Journal of Clinical Oncology.

“Mucosal melanoma is a highly vascularized tumor with an extremely poor prognosis,” the study authors wrote.

“The (Avastin with paclitaxel and carboplatin) protocol could be an alternative for the treatment of advanced (mucosal melanoma) in immunotherapies-ineligible or immunotherapies-failure population.”

READ THE ORIGINAL FULL ARTICLE